Back in 2014, Roche spent $725 million upfront on Seragon Pharmaceuticals, but three years down the line, it has now canned work on its leading drug, ARN-810.
In its first-quarter results announced today, the Swiss major quietly announced that the next-gen SERD drug, RG6046, has been “removed from phase 2” in HER negative advanced breast cancer.
No other details were given, but the compound appears to have been removed from the company’s roster of pipeline meds.
Roche paid $725 million (with $1 billion in biobucks) for Seragon, a privately held biotech based in San Diego, California, three years ago.
Roche got access to Seragon’s entire portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs) for the potential treatment of hormone receptor-positive breast cancer. ARN-810 had been leading that pack, and was in phase 1 when it was subsumed into Roche.
Other meds from its buyout are still lined up in its pipeline, however, including RG6047 (GDC-0927, or ARN-927).
By Ben Adams
Source: Fierce Biotech
The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.
Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.
Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.